Halia Therapeutics CEO Dr. David Bearss is quoted;

Aging

“The biopharma industry is undergoing a transformative shift, driven by longevity science and the need to manage chronic diseases,” said David Bearss, CEO of Halia Therapeutics. “GLP-1 agonist drugs have sparked new thinking in addressing aging populations and declining birth rates, marking the beginning of a new pivot toward therapies that not only treat but also prevent chronic conditions, extending both lifespan and healthspan. As innovative treatments targeting the root causes of aging and chronic conditions approach clinical trials, we must adopt new development and regulatory frameworks to foster these breakthroughs.”

Read full article here